Chronic viral hepatitis D - the current state of a problem.

Хронический вирусный гепатит Д - современное состояние проблемы.
Aliya Konysbekova 1 2
More Detail
1 JSC «Medical University Astana», Department of gastroenterology and infectious diseases, Astana, Republic of Kazakhstan
2 KF “UMC”, Republican diagnostic center, Astana, Kazakhstan
J CLIN MED KAZ, Volume 1, Issue 43, pp. 11-14. https://doi.org/10.23950/1812-2892-JCMK-00388
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Chronic hepatitis D- severe and rapidly progressing form of viral hepatitis, leading to the liver cirrhosis in 70% of cases within 5-10 years. HDV RNA replicates only in the presence of viral hepatitis B. Introduction to the calendar of immunization vaccination in the Republic of Kazakhstan led to a reduction in the incidence of hepatitis B is almost 40 times. However, despite the ongoing effective measures, the amount of detectable virus mixed in with the delta agent is increased and is now at a global map of Kazakhstan refers to medium-endemic countries. Against the background of rapid progress in the treatment of hepatitis C, hepatitis B treatment of existing schemes in the delta agent ineffective, allowing HDV considered as one of the most virulent and dangerous hepatotropic virus.

CITATION

Konysbekova A. Chronic viral hepatitis D - the current state of a problem.. Journal of Clinical Medicine of Kazakhstan. 2017;1(43):11-4. https://doi.org/10.23950/1812-2892-JCMK-00388

REFERENCES

  • EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57:167–185.
  • Abdurahmanov D.T., Hronicheskiy gepatit V i D (Chronic hepatitis B and D), M., GEOTAR Media, 2010; 288 p.
  • Rizzetto M., Alessia C. Epidemiology of Hepatitis D. Semin. Liver. Dis. 2012; 32:211–219.
  • Kaliaskarova K.S. Faktoryi progressirovaniya hronicheskih virusnyih gepatitov V, S v korennoy populyatsii Kazahstana : avtoreferat dis. ... d-ra med. nauk - Karaganda, 2010; 24 p.
  • Degertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008; 28(4):494-8.
  • Nersesov A.V., i dr . Rasprostranennost virusnyih gepatitov sredi zhiteley Yuzhno-Kazahstanskoy oblasti (The prevalence of viral hepatitis among residents of the South Kazakhstan region), Medicine (Almaty). 2016; 9(171):30-33.
  • Hazanov A.I., Vasilev A.P., Pehtashev S.G. i dr. Znachenie osnovnyih i dobavochnyih etiologicheskih faktorov v razvitii HBV- i HCV-tsirrozov pecheni (The importance of the main and additional etiological factors in the development of HBV and HCV cirrhosis), Ros. zhurn. gastroenterol. gepatol. koloproktl. 2001; 4:8-12
  • Amosov A. D., Gepatit V: inform.-metod. Posobie, A. D. Amosov. M., 2006; pp. 100-103.
  • Kaliaskarova K.S., Primenenie Pegintrona pri 1b genotipe hronicheskogo gepatita S u kazahov (The use of Pegintron at 1b genotype of chronic hepatitis C in Kazakhs), Meditsinskiy vestnik Severnogo Kavkaza, 2008; 3:13-14.
  • Rizzetto M. Hepatitis D: Thirty years after. J. Hepatol. 2009; 50:1043–1050.
  • Wedemeyer H., Manns M. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat. Rev. Gastroenterol. Hepatol. 2010; 7:31.
  • Wedemeyer H., Yurdaydin C., Dalekos G. et al. Peginterferon plus Adefovir versus either drug alone for hepatitis delta. NEJM. 201; 364:322–331.
  • Rizzetto M, Niro GA. Myrcludex B, a novel therapy for chronic hepatitis D?. Journal of hepatology. 2016 Sep 1;65(3):465-6.
  • Shahgildyan I.V i dr., Epidemiologicheskie zakonomernosti i sovremennyie podhodyi k vaktsinoprofilaktike gepatita B (Epidemiological patterns and modern approaches to the vaccine prophylaxis of hepatitis B), Gepatologiya. 2003; 2:4 – 10.
  • Ivashkin, V.T., Kletochnaya i molekulyarnaya biologiya vospaleniya pecheni (Cellular and molecular biology of liver inflammation), Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 1998; 5:13-17.
  • Bueverov, A.O., Immunologicheskie mehanizmyi povrezhdeniya pecheni (Immunological mechanisms of liver damage), Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 1998; 5:18-21.